Breast Cancer
Conditions
Keywords
Breast cancer, Metastatic, HER2 positive, vinorelbine
Brief summary
This phase II study will investigate oral vinorelbine 90 mg/m2 on days 1 + 8 at 3 weeks intervals in combination with trastuzumab as 1st and 2nd line treatment of women with metastatic HER2 positive breast cancer. Oral vinorelbine has shown the same overall response rate as i.v. vinorelbine in metastatic breast cancer, and capsules are generally better tolerated.
Interventions
DRUGTrastuzumab
Initial dose 8 mg/kg i.v. Subsequently, 6 mg/kg i.v. at intervals of 3 weeks
DRUGVinorelbine
Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsule on day 1 to be taken at the hospital, and on day 8 at home.
Sponsors
Vejle Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Woman ≥ 18 years of age. * PS 0-2. Expected lifetime of more than 12 weeks. * Histologically verified breast cancer(adenocarcinoma) * Primary tumor or metastasis is HER2 positive with IHC3+ or FISH+ (ratio ≥ 2.2). * Documented metastatic breast cancer with min. one lesion measureable according to the RECIST 1.1 criteria. All solitary lesions must be verified cytologically/histologically if representing the only evidence of malignancy. * The patient may have received (neo-) adjuvant chemotherapy (taxanes, anthracyclines and trastuzumab) and 1st line chemotherapy in combination with trastuzumab for metastatic disease. * The patient may have received previous adjuvant antihormonal treatment for metastatic breast cancer. * The patient may receive radiation therapy, however, not against lesions used for response evaluation. * Normal heart function, LVEF ≥ 50% measured by MUGA/EKKO. * Normal bone marrow function: Hemoglobin ≥ 6 mmol/l, ANC ≥ 1.5x10\^9/l. Thrombocytes ≥ 100x10\^9/l. * Normal liver function: Bilirubin ≤ 1.5 x upper normal level, ALAT ≤ 2.5 x upper normal level, BASP ≤ 2.5 x upper normal level (≤ 5 if presence of bone metastases). * Normal renal function: Creatinine ≤ upper normal level. In case of raised creatinine the measured/calculated GFR must be ≥ 50 ml/min. * Fertile women must present a negative pregnancy test and use contraceptives during and 3 months after treatment. An IUD without hormone is considered a safe contraceptive. * Written and orally informed consent prior to any study related procedure.
Exclusion criteria
* Local recurrence or counter-lateral breast cancer without other dissemination. * Pregnant or breastfeeding women. * Clinical symptoms of CNS metastases, incl. meningeal carcinomatosis. * Malabsorption syndrome or other disease affecting the gastrointestinal function. Resection of the ventriculus or the small intestine, which can affect absorption of oral vinorelbine. * Dysphagia or other conditions preventing the patient from swallowing tablets. * Mental or social conditions preventing treatment or follow-up. * Serious concurrent medical condition, such as: * AMI within 12 months or unstable angina. * Heart incompensation NYHA III or IV or uncontrolled hypertension (systolic \> 150 mm/hg and/or diastolic \>100 mm/hg). * Serious arrythmia requiring medication, excl. atrial fibrillation and paroxystic supraventricular tachycardia. * Active infection, uncontrolled diabetes or hypercalcemia. * Other concurrent experimental treatment. * Concurrent antihormonal treatment of metastatic breast cancer. * Known neuropathia ≥ grade 2. * Other previous malignant disease within the past 5 years excl. non-melanoma skin cancer and carcinoma in situ cervicis uteri. * Previous treatment with vinca alkaloid. * Previous serious allergic or unexpected reactions to trastuzumab treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | Every 9 weeks. Up to 2 years | CT scan and MUGA scan |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | Every 9 weeks from date of first treatment until progression or death. Up to 2 years | CT scan |
| Overall Survival | From date of inclusion until date of death. Up to 2 years. | — |
Countries
Denmark
Outcome results
None listed